The National Academy of Science has created a roadmap for human genome editing. "They laid out clear criteria and conditions that must be met before any clinical trial can be considered. In order to clear a path for germline editing, the following are necessary: There must be an absence of a reasonable alternative which may include a baby being born and treated after birth with somatic editing intervention. The technology will be restricted to prevention of a serious disease or condition. A gene may only be edited when there is a strong understanding of the particular gene that is going to be altered and that the gene may not be changed to a novel form, but, only to the form commonly found in healthy people. Credible preclinical data on the potential health benefits of performing the genome editing must be in existence. An actual protocol requires a regulatory agency capable of ongoing oversight throughout the study -- consistent with patient privacy and with maximum transparency."
Shared publiclyView activity
Related Collections